Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DCTH, FENC, XERS, SVRA, VSTM, and represent 49.65% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: VSTM (+$7.1M), FENC, HELP, ABVX, Sellas Life Sciences Group I, TLPH, RGNT, NRXS, SPRB, PEPG.
- Started 9 new stock positions in Tenax Therapeutics, Spdr S&p Oil & Gas Exp & Pr put, Cg Oncology, SPRB, ABVX, Ishares Tr Index option, PEPG, Sellas Life Sciences Group I, Eyepoint Pharmaceuticals.
- Reduced shares in these 10 stocks: CGON (-$6.8M), PCVX (-$5.2M), VRDN, CLDX, Replimune Group, XERS, DFTX, BCRX, LPCN, OKUR.
- Sold out of its positions in ANNX, Arrivent Biopharma, AVTX, CGON, DFTX, Powershares Qqq Etf Put Opt 01/19 154.0 put, LPCN, Replimune Group, Spdr S&p 500 Etf Tr option, VRDN. Viridian Therapeutics, Uniqure Nv call.
- Rosalind Advisors was a net seller of stock by $-17M.
- Rosalind Advisors has $269M in assets under management (AUM), dropping by 8.16%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 35 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Delcath Systems Com New (DCTH) | 15.4 | $42M | 3.3M | 12.59 |
|
|
| Fennec Pharmaceuticals (FENC) | 12.7 | $34M | +9% | 3.2M | 10.75 |
|
| Xeris Pharmaceuticals (XERS) | 8.6 | $23M | -9% | 2.9M | 7.92 |
|
| Savara (SVRA) | 7.3 | $20M | 3.2M | 6.16 |
|
|
| Verastem Com New (VSTM) | 5.7 | $15M | +86% | 4.0M | 3.82 |
|
| X4 Pharmaceuticals Com New (XFOR) | 5.6 | $15M | 3.2M | 4.67 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 5.2 | $14M | -4% | 988k | 14.30 |
|
| Cybin Com New (HELP) | 4.8 | $13M | +27% | 2.0M | 6.61 |
|
| Vor Biopharma Com New (VOR) | 4.4 | $12M | -7% | 649k | 18.41 |
|
| Vaxcyte (PCVX) | 4.3 | $12M | -31% | 200k | 58.13 |
|
| Mediwound Shs New (MDWD) | 4.1 | $11M | 749k | 14.70 |
|
|
| Celldex Therapeutics Com New (CLDX) | 2.8 | $7.4M | -39% | 200k | 37.21 |
|
| BioCryst Pharmaceuticals (BCRX) | 2.7 | $7.2M | -21% | 722k | 10.00 |
|
| Profound Medical Corp Com New (PROF) | 2.0 | $5.5M | 828k | 6.65 |
|
|
| Talphera Com New (TLPH) | 2.0 | $5.3M | +54% | 5.2M | 1.03 |
|
| Atea Pharmaceuticals (AVIR) | 1.8 | $5.0M | -8% | 1.1M | 4.65 |
|
| Myomo Com New (MYO) | 1.4 | $3.8M | -5% | 3.6M | 1.04 |
|
| Ovid Therapeutics (OVID) | 1.1 | $3.0M | 1.1M | 2.69 |
|
|
| Neuraxis (NRXS) | 1.1 | $3.0M | +77% | 508k | 5.85 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $2.8M | NEW | 21k | 133.26 |
|
| Inspiremd (NSPR) | 1.0 | $2.7M | 3.9M | 0.70 |
|
|
| Regentis Biomaterials Ordinary Shares (RGNT) | 0.9 | $2.5M | +178% | 702k | 3.53 |
|
| Sellas Life Sciences Group Put Put Option | 0.9 | $2.3M | NEW | 569k | 4.05 |
|
| Polypid (PYPD) | 0.7 | $2.0M | -34% | 390k | 5.08 |
|
| Biofrontera Com New (BFRI) | 0.4 | $1.2M | +9% | 1.3M | 0.95 |
|
| Kura Oncology (KURA) | 0.4 | $1.1M | 100k | 10.97 |
|
|
| Spruce Biosciences Com New (SPRB) | 0.4 | $1.1M | NEW | 20k | 54.00 |
|
| Aquestive Therapeutics (AQST) | 0.4 | $1.0M | 250k | 4.16 |
|
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.3 | $684k | -66% | 150k | 4.56 |
|
| Pepgen (PEPG) | 0.2 | $630k | NEW | 350k | 1.80 |
|
| Cg Oncology Call Call Option | 0.1 | $375k | NEW | 31k | 12.10 |
|
| Eyepoint Pharmaceuticals Call Call Option | 0.0 | $131k | NEW | 50k | 2.60 |
|
| Ishares Tr Put Put Option | 0.0 | $110k | NEW | 500k | 0.22 |
|
| Spdr Series Trust Put Put Option | 0.0 | $35k | NEW | 141k | 0.25 |
|
| Tenax Therapeutics Put Put Option | 0.0 | $14k | NEW | 6.2k | 2.25 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2026 Q2 filed Aug. 14, 2026
- Rosalind Advisors 2026 Q1 filed May 14, 2026
- Rosalind Advisors 2025 Q4 filed Feb. 12, 2026
- Rosalind Advisors 2025 Q3 filed Nov. 13, 2025
- Rosalind Advisors 2025 Q2 filed Aug. 14, 2025
- Rosalind Advisors 2025 Q1 filed May 14, 2025
- Rosalind Advisors 2024 Q4 restated filed Feb. 14, 2025
- Rosalind Advisors 2024 Q3 filed Oct. 30, 2024
- Rosalind Advisors 2024 Q2 filed July 12, 2024
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024